The t(4;14)(p16.3;q32.3) is found in 15% of presenting multiple myeloma (MM) cases and is associated with a significantly worse prognosis than other biological subgroups. As a consequence of the translocation, two genes are aberrantly expressed, the fibroblast growth factor receptor 3 (*FGFR3*) and a multiple myeloma SET domain containing protein, *MMSET* (*WHSC1/NSD2*), both of which have potential oncogenic activity.^[@bib1]^ Importantly, FGFR3 shows only weak transforming activity and is eventually lost in 30% of patients,^[@bib2]^ suggesting that it is not the main oncogenic factor. In contrast, *MMSET* gene overexpression is universal, and when it is knocked down experimentally, there is inhibition of proliferation, induction of apoptosis and alteration of cell adhesion,^[@bib3],\ [@bib4],\ [@bib5]^ suggesting it is central to the pathogenesis of this subtype of MM. MMSET is known to have histone methyl transferase activity^[@bib6]^ and is deregulated early on in the genesis of developing myeloma, and could therefore constitute a good therapeutic target. The *MMSET* locus in t(4;14) myeloma patients has a complicated genomic structure and after translocation events and RNA splicing, a number of different transcripts are generated ([Figure 1](#fig1){ref-type="fig"}). This genetic complexity of *MMSET* has been added to recently by the discovery of the H/ACA box RNA *ACA11* (*SCARNA22*), that has been found within intron 20 of *MMSET* and is also overexpressed in the t(4;14) subgroup.^[@bib7]^ This small RNA has been suggested to be key to the pathogenesis of t(4;14) MM, raising the question that it may constitute the main therapeutic target.

The box H/ACA RNAs are a group of small nucleolar RNA (snoRNA) conserved from Archea to mammals. These RNAs are generally associated with a multi-protein complex, and usually function as a guide to the site-specific pseudouridylation of rRNA and spliceosomal small nuclear RNAs. However, they are also involved in other regulatory complexes, such as telomerase,^[@bib8]^ but their full biological roles have not been completely elucidated. More than 90% of human snoRNA genes are encoded within spliced introns,^[@bib9]^ and their expression is closely linked to the transcription of the host gene.^[@bib9],\ [@bib10]^ After host gene transcription, the intronic snoRNAs are trimmed to a mature form by exonucleolytic activities. The mRNA splicing machinery may chaperone snoRNA post-transcriptional maturation steps, but in some cases, these steps are splicing-independent.^[@bib11]^ However, there are a few cases in mammals where snoRNAs are independently transcribed, for instance, the gene for the telomerase RNA component (*terC*) or the RNAs involved in the pre-rRNA endonucleolytic processing,^[@bib8],\ [@bib9]^ but this is a rare event.

In a series of experiments it has been shown that *ACA11* knockdown impairs cell proliferation and deregulates the oxidative stress response, and its overexpression downregulates the transcription of ribosomal protein genes.^[@bib7]^ The same group, on the basis of experiments showing that t(4;14) cell lines knocked out for *MMSET*, either on the translocated allele (TKO) or on the non-translocated allele (NTKO), have lower *ACA11* levels compared wih their parental cell line (KMS11) with a normal overexpressed *MMSET*, suggested that *ACA11*, rather than MMSET, is the key pathogenic gene in t(4;14) MM. In previous studies, the same TKO model system had been used to prove the oncogenic effect of MMSET in myeloma;^[@bib5],\ [@bib6]^ however, in these more recent experiments where *ACA11* was knocked down, the key implication of the work seemed to shift the pathogenic importance from MMSET to *ACA11.*^[@bib7]^

However, when we examined these results in detail, some of the results do not seem to accurately reflect what is understood about the TKO cell line system biology. In particular, the *MMSET* gene was erroneously reported to be deleted, whereas, in fact, the TKO and NTKO cell lines were generated from the parental KMS11 t(4;14) line, by deleting *MMSET* exon 7 only^[@bib5]^ ([Figure 1](#fig1){ref-type="fig"}). This deletion creates a frame shift that introduces an earlier STOP codon, leaving the level of *MMSET* mRNA unaltered, and in theory, *ACA11* untouched. Moreover, both TKO and NTKO cell lines express the MMSET isoform REIIBP.^[@bib5]^ *REIIBP* mRNA is transcribed from an intronic promoter downstream of both the TKO and NTKO knockout mutation^[@bib12]^ ([Figure 1](#fig1){ref-type="fig"}), and harbors intron 20, the location of the *ACA11* gene. In order to reconcile the observations reported in the paper with what we understand about the biology of *MMSET* and other human intronic snoRNAs, we would have to hypothesize that *ACA11* biogenesis in myeloma is different. It could be possible that *ACA11*, even though it is localized within an *MMSET* intron, could have an independent transcription start site distinct from the *MMSET/REIIBP* gene, or alternatively it may be regulated at the post-transcriptional level. However, as TKO, NTKO and KMS11 are con-isogenic lines, differing only for the level of functional MMSET, differential *ACA11* regulation could only be due to a direct or indirect role of MMSET.

In order to resolve these discrepancies, we investigated *MMSET* and *ACA11* expression in 153 myeloma patients as well as in the same set of con-isogenic cell lines. Statistical analysis showed that there is a good correlation between the expression of both genes ([Figure 2a](#fig2){ref-type="fig"}), suggesting that their regulation is interdependent. A similar result was found by an independent study recently.^[@bib13]^ This observation was also corroborated by ENCODE RNA sequencing (RNA-seq) data,^[@bib14]^ in which *MMSET* and *ACA11* RNAs expression in non-myeloma lines were also frequently co-expressed. The results of this work are consistent with *ACA11* biogenesis being via a classical intronic mechanism. Further, we went on to show that *ACA11* expression was indeed lower in TKO cells, using RNA-seq on TKO and its parental KMS11 cell lines. We found that both lines had equal levels of signal coming from *MMSET* exons, ([Figure 2b](#fig2){ref-type="fig"}). As an internal control, we were able to demonstrate that exon 7 signal levels were reduced in TKO. We describe an intronic signal peak present in both cell lines, derived from intron 20 ([Figure 2b](#fig2){ref-type="fig"}), which is of comparable intensity and perfectly overlapping with the position of the *ACA11* gene. This result demonstrates that in both lines the snoRNA is intact and is present in equal amount.

To confirm and better characterize this result, we designed and used a qRT-PCR test and applied it to total RNA from KMS11, TKO and NTKO looking at the expression of *ACA11* and *MMSET*. In this experiment, we compared these values to those from HeLa, RPMI-8226 (t(4;14) negative MM line) and TKO::MMSET (TKO line virally transduced with the intronless cDNA for *MMSET*, and hence not carrying *ACA11*), ([Figure 2c](#fig2){ref-type="fig"}). We demonstrated a marked difference in *MMSET* and *ACA11* expression between t(4;14) positive and negative lines. However, in contrast, we could not demonstrate a difference in *MMSET* mRNA in TKO, KMS11 and NTKO lines, even if these lines have different level of MMSET protein.^[@bib5],\ [@bib6]^

Taking the RNA-seq and qRT-PCR data as whole, they show that *ACA11* expression directly mirrors *MMSET* expression level, highlighting the correlation demonstrated in primary patient material ([Figure 2a](#fig2){ref-type="fig"}). We also show that *ACA11* expression is neither deregulated in the TKO nor in the NTKO cell line compared with parental KMS11. This result is compatible with the *ACA11* snoRNA being generated by excision from the *MMSET* mRNA. Alternatively, if *ACA11* had an independent promoter from *MMSET* isoforms, it must be under the control of the same enhancer that regulates *MMSET* and *REIIBP* expression (the *IgH* enhancer or the *MMSET* enhancer in non-t(4;14) samples). Interestingly, we saw that in TKO::MMSET, the *ACA11* level was very close to those of TKO and KMS11, even if MMSET levels were virally transduced to be four-times higher. This observation shows that MMSET has no role in directly regulating *ACA11* gene expression or in regulating its post-transcriptional maturation steps.

Overall, the data presented here are consistent with MMSET being the key pathologic mediator in t(4;14) myeloma.^[@bib6]^ We do, however, think that *ACA11* has an important role in t(4;14) pathogenesis, because evolutionary pressure seems to have kept *ACA11* inside the *MMSET* locus, and often, intronic RNA are found to be involved in the same biochemical pathway as their host gene.^[@bib9]^
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![MMSET genetic map on chromosome 4. The position of the different translocation events in MM is shown by slashed lines. Gray and black ovals indicate non-coding and coding exons, respectively; dotted straight line between exons represent the introns. Splicing event for the canonical longest *MMSET* isoform is shown by joining lines between exons. Exons 4a and 11, shown by white triangles, are used only for alternative splicing and are not present in the longest *MMSET* isoform. Exon 7, deleted in TKO and NTKO lines, is indicated by a white star. Transcription start sites and first translated codons (ATG) for *MMSET* and *REIIBP* are indicated, respectively, by bent black arrows and open arrows. Genomic position for *ACA11* is shown by a white arrow.](bcj20139f1){#fig1}

![Correlation between MMSET expression and ACA11 expression. (**a**) Scatter plot showing a positive correlation between *ACA11* expression (by Affymetrix GeneChip microRNA arrays v1.0; Affymetrix, Santa Clara, CA, USA) and *MMSET* (222777_s\_at) expression (by Affymetrix HG-U133 Plus 2.0 arrays) in 153 subjects from Myeloma IX with the Pearson\'s correlation coefficient (*r*) of 0.36 and the two-tail *P*-value of 0.000005 (**b**) *ACA11* is expressed in *MMSET* knockout cell lines. RNA-seq analysis was performed using the methods and tools described here^[@bib15]^ and visualized using IGV (Integrative Genome Viewer, Broad Institute). Number below the filled boxes show the relative position for *MMSET* exons; straight lines between exons represent the introns. Arrow head indicates genomic *ACA11* position. KMS11 line was provided by Dr Otsuki (Kawasaki Medical School, Japan), TKO and NTKO by J Lauring (Johns Hopkins, Balltimore). (**c**) qRT-PCR values for *MMSET* and *ACA11*. The results are expressed relative to human β-Actin. Contamination for genomic DNA was tested by performing cDNA synthesis in the absence of reverse transcriptase and amplifying the samples with primers for a control region on chromosome 12. The error bars depicted are the standard deviations from two to four separate RNA extractions and cDNA syntheses. TKO::MMSET was generated by viral transduction cloning *MMSET* cDNA into pRRLSIN lentivector.](bcj20139f2){#fig2}
